539 related articles for article (PubMed ID: 31831255)
1. Sjögren's syndrome: Old and new therapeutic targets.
Mavragani CP; Moutsopoulos HM
J Autoimmun; 2020 Jun; 110():102364. PubMed ID: 31831255
[TBL] [Abstract][Full Text] [Related]
2. Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren's syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
Blokland SLM; Hillen MR; Wichers CGK; Zimmermann M; Kruize AA; Radstake TRDJ; Broen JCA; van Roon JAG
RMD Open; 2019; 5(1):e000701. PubMed ID: 30713717
[No Abstract] [Full Text] [Related]
3. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and New Strategies for Primary Sjögren's Syndrome.
Mavragani CP
Annu Rev Med; 2017 Jan; 68():331-343. PubMed ID: 28099084
[TBL] [Abstract][Full Text] [Related]
5. Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.
Srivastava A; Makarenkova HP
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271951
[TBL] [Abstract][Full Text] [Related]
6. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome.
Brito-Zerón P; Ramos-Casals M;
Curr Opin Rheumatol; 2014 Sep; 26(5):520-7. PubMed ID: 25050925
[TBL] [Abstract][Full Text] [Related]
7. One year in review 2016: Sjögren's syndrome.
Ferro F; Vagelli R; Bruni C; Cafaro G; Marcucci E; Bartoloni E; Baldini C
Clin Exp Rheumatol; 2016; 34(2):161-71. PubMed ID: 27095672
[TBL] [Abstract][Full Text] [Related]
8. Inflammation in Sjögren's syndrome: Cause or consequence?
Rodrigues AR; Soares R
Autoimmunity; 2017 May; 50(3):141-150. PubMed ID: 28276715
[TBL] [Abstract][Full Text] [Related]
9. Advances in the diagnosis and treatment of Sjogren's syndrome.
Chen X; Wu H; Wei W
Clin Rheumatol; 2018 Jul; 37(7):1743-1749. PubMed ID: 29804149
[TBL] [Abstract][Full Text] [Related]
10. Biologic treatment in Sjögren's syndrome.
Sada PR; Isenberg D; Ciurtin C
Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
Mariette X; Gottenberg JE
Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
[TBL] [Abstract][Full Text] [Related]
12. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of Sjögren's syndrome.
García-Carrasco M; Fuentes-Alexandro S; Escárcega RO; Salgado G; Riebeling C; Cervera R
Arch Med Res; 2006 Nov; 37(8):921-32. PubMed ID: 17045106
[TBL] [Abstract][Full Text] [Related]
14. Dual function of miR-1248 links interferon induction and calcium signaling defects in Sjögren's syndrome.
Jang SI; Tandon M; Teos L; Zheng C; Warner BM; Alevizos I
EBioMedicine; 2019 Oct; 48():526-538. PubMed ID: 31597594
[TBL] [Abstract][Full Text] [Related]
15. Current Insights in Microbiome Shifts in Sjogren's Syndrome and Possible Therapeutic Interventions.
Tsigalou C; Stavropoulou E; Bezirtzoglou E
Front Immunol; 2018; 9():1106. PubMed ID: 29881381
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the role of T cells in the pathogenesis of Sjögren's syndrome for therapeutic treatment.
An Q; Zhao J; Zhu X; Yang B; Wu Z; Su Y; Zhang L; Xu K; Ma D
Front Immunol; 2022; 13():995895. PubMed ID: 36389806
[TBL] [Abstract][Full Text] [Related]
17. Correction of autophagy impairment inhibits pathology in the NOD.H-2h4 mouse model of primary Sjögren's syndrome.
Voynova E; Lefebvre F; Qadri A; Muller S
J Autoimmun; 2020 Mar; 108():102418. PubMed ID: 32029330
[TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
Hansen A; Lipsky PE; Dörner T
Curr Opin Rheumatol; 2005 Sep; 17(5):558-65. PubMed ID: 16093833
[TBL] [Abstract][Full Text] [Related]
19. [B lymphocytes in Sjögren's syndrome].
Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
[TBL] [Abstract][Full Text] [Related]
20. Emerging biological therapies in primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P
Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
